Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Net Cash Flow (2017 - 2025)

Cue Biopharma's Net Cash Flow history spans 9 years, with the latest figure at -$15.8 million for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 760.16% year-over-year to -$15.8 million; the TTM value through Sep 2025 reached -$20.7 million, up 6.96%, while the annual FY2024 figure was -$26.1 million, 740.72% down from the prior year.
  • Net Cash Flow for Q3 2025 was -$15.8 million at Cue Biopharma, down from $14.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $21.9 million in Q4 2022 and bottomed at -$36.4 million in Q3 2022.
  • The 5-year median for Net Cash Flow is -$3.3 million (2021), against an average of -$3.3 million.
  • The largest annual shift saw Net Cash Flow surged 770.93% in 2022 before it plummeted 760.16% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$3.3 million in 2021, then soared by 770.93% to $21.9 million in 2022, then crashed by 128.22% to -$6.2 million in 2023, then tumbled by 61.29% to -$10.0 million in 2024, then plummeted by 58.53% to -$15.8 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Net Cash Flow are -$15.8 million (Q3 2025), $14.4 million (Q2 2025), and -$9.3 million (Q1 2025).